DK1067917T3 - Fremgangsmåde til behandling af dopaminerge og GABA-nerge lidelser - Google Patents

Fremgangsmåde til behandling af dopaminerge og GABA-nerge lidelser

Info

Publication number
DK1067917T3
DK1067917T3 DK98937104T DK98937104T DK1067917T3 DK 1067917 T3 DK1067917 T3 DK 1067917T3 DK 98937104 T DK98937104 T DK 98937104T DK 98937104 T DK98937104 T DK 98937104T DK 1067917 T3 DK1067917 T3 DK 1067917T3
Authority
DK
Denmark
Prior art keywords
gaba
hedgehog
dopaminergic
nerve disorders
mimicking agents
Prior art date
Application number
DK98937104T
Other languages
Danish (da)
English (en)
Inventor
Ningning Miao
Monica Wang
Nagesh K Mahanthappa
Kevin Pang
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of DK1067917T3 publication Critical patent/DK1067917T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK98937104T 1997-07-24 1998-07-24 Fremgangsmåde til behandling af dopaminerge og GABA-nerge lidelser DK1067917T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/900,220 US7144997B2 (en) 1997-07-24 1997-07-24 Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto

Publications (1)

Publication Number Publication Date
DK1067917T3 true DK1067917T3 (da) 2006-04-18

Family

ID=25412184

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98937104T DK1067917T3 (da) 1997-07-24 1998-07-24 Fremgangsmåde til behandling af dopaminerge og GABA-nerge lidelser

Country Status (10)

Country Link
US (3) US7144997B2 (ja)
EP (2) EP1723950A2 (ja)
JP (1) JP2001510796A (ja)
AT (1) ATE311863T1 (ja)
AU (1) AU8589398A (ja)
CA (1) CA2297410A1 (ja)
DE (1) DE69832730T2 (ja)
DK (1) DK1067917T3 (ja)
ES (1) ES2253822T3 (ja)
WO (1) WO1999004775A2 (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH114695A (ja) * 1997-04-25 1999-01-12 Hayashibara Biochem Lab Inc ヘッジホッグ蛋白質
AU8173098A (en) 1997-06-27 1999-01-19 Ontogeny, Inc. Neuroprotective methods and reagents
US7144997B2 (en) 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
US6639051B2 (en) 1997-10-20 2003-10-28 Curis, Inc. Regulation of epithelial tissue by hedgehog-like polypeptides, and formulations and uses related thereto
AU1716599A (en) 1997-12-08 1999-06-28 Curis, Inc. Human patched genes and proteins, and uses related thereto
US6667176B1 (en) 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US7410798B2 (en) 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
US6884770B1 (en) 1998-11-06 2005-04-26 Curis, Inc. Methods and compositions for treating or preventing peripheral neuropathies
US20030083242A1 (en) * 1998-11-06 2003-05-01 Alphonse Galdes Methods and compositions for treating or preventing peripheral neuropathies
US20050042749A1 (en) 2001-05-16 2005-02-24 Carpenter Melissa K. Dopaminergic neurons and proliferation-competent precursor cells for treating Parkinson's disease
EP1287116A2 (en) 2000-05-17 2003-03-05 Geron Corporation Neural progenitor cell populations
US7250294B2 (en) 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
JP2002348239A (ja) * 2000-10-05 2002-12-04 Takeda Chem Ind Ltd 幹細胞・神経前駆細胞の増殖・分化促進剤
ATE529512T1 (de) * 2002-02-01 2011-11-15 Life Technologies Corp Doppelsträngige oligonukleotide
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
GB2421029B (en) * 2003-08-29 2008-04-09 Wisconsin Alumni Res Found Method of in vitro differentiation of neural stem cells, motor neurons and dopamine neurons from primate embryonic stem cells
MXPA06006659A (es) * 2003-12-19 2006-08-31 Curis Inc Composicion y metodos para modular la actividad del sistema nervioso central.
EP1786473A4 (en) 2004-08-11 2008-11-19 Cedars Sinai Medical Center TREATMENT OF PARKINSON DISEASE AND RELATED DISEASES
US7858590B2 (en) 2005-08-11 2010-12-28 Cedars-Sinai Medical Center Treatment of parkinson's disease and related disorders
US10160950B2 (en) 2013-03-01 2018-12-25 Wisconsin Alumni Research Foundation Methods of maintaining, expanding and differentiating neuronal subtype specific progenitors
US20140248696A1 (en) * 2013-03-01 2014-09-04 Wisconsin Alumni Research Foundation Methods of maintaining, expanding, and diffrentiating neuronal subtype specific progenitors
WO2018129421A1 (en) * 2017-01-09 2018-07-12 Genervon Biopharmaceuticals, LLC A promising drug candidate for parkinson's disease

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4456687A (en) 1978-11-16 1984-06-26 President And Fellows Of Harvard College Agents for promoting growth of epithelial cells
EP0187371B1 (en) 1984-12-27 1991-06-19 Asahi Kasei Kogyo Kabushiki Kaisha Substituted isoquinolinesulfonyl compounds
DE3786714T2 (de) 1986-06-16 1994-03-10 Daiichi Seiyaku Co Therapeutisches Mittel für Hautgeschwüre.
JPH0745383B2 (ja) 1986-09-30 1995-05-17 第一製薬株式会社 環状アデノシン誘導体含有毛髪用剤
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
DE3942114C2 (de) 1988-12-26 1997-09-04 Hiroyoshi Hidaka Verbindungen mit einer Wirkung für eine gleichmäßige Gefäßmuskelentspannung und pharmazeutische Zusammensetzung, die diese enthält
EP0464206A4 (en) 1989-03-24 1992-05-13 Daiichi Pharmaceutical Co., Ltd. Drug for improving brain function
JPH02273610A (ja) 1989-04-17 1990-11-08 Chugai Pharmaceut Co Ltd 発毛促進剤
JPH0725786A (ja) 1990-05-16 1995-01-27 Univ Rockefeller アルツハイマー病を伴うアミロイドーシスの治療
JPH04305528A (ja) 1991-02-22 1992-10-28 Dai Ichi Seiyaku Co Ltd ケラチノサイト及び皮膚線維芽細胞の増殖刺激剤
ATE363532T1 (de) 1991-03-01 2007-06-15 Dyax Corp Verfahren zur herstellung bindender miniproteine
US5223408A (en) 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
WO1993008809A1 (en) 1991-11-08 1993-05-13 The University Of Southern California Compositions containing k-252 compounds for potentiation of neurotrophin activity
US5461146A (en) 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
JP2893029B2 (ja) 1992-08-10 1999-05-17 旭化成工業株式会社 心臓保護剤
US6333168B1 (en) 1993-05-20 2001-12-25 The Trustees Of Columbia University In The City Of New York Cloning, expression and uses of dorsalin-1
US5519035A (en) 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
US5789543A (en) 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
US6610656B1 (en) * 1993-12-30 2003-08-26 President And Fellows Of Harvard College Method of promoting chondrocyte differentiation with hedgehog related polypeptides
US6165747A (en) * 1993-12-30 2000-12-26 President & Fellows Of Harvard College Nucleic acids encoding hedgehog proteins
US6884775B1 (en) * 1993-12-30 2005-04-26 President And Fellows Of Harvard College Methods and compositions for regulating skeletogenic formation
US6261786B1 (en) * 1993-12-30 2001-07-17 Imperial Cancer Res. Technology Screening assays for hedgehog agonists and antagonists
US6384192B1 (en) * 1993-12-30 2002-05-07 President & Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins
US20030186357A1 (en) * 1993-12-30 2003-10-02 Philip W. Ingham Vertebrate embryonic pattern-inducing proteins, and uses related thereto
US7060450B1 (en) * 1993-12-30 2006-06-13 President And Fellows Of Harvard College Screening assays for agonists and antagonists of the hedgehog signaling pathway
EP0741783B1 (en) 1993-12-30 2009-03-18 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing hedgehog-like proteins
WO1995023223A1 (en) 1994-02-25 1995-08-31 The Trustees Of Columbia University In The City Of New York Dna encoding the vertebrate homolog of hedgehog, vhh-1, expressed by the notochord, and uses thereof
US5585087A (en) 1994-06-08 1996-12-17 President And Fellows Of Harvard College Assay for identifying extracellular signaling proteins
US5554608A (en) 1994-09-28 1996-09-10 Ahluwalia; Gurpreet S. Inhibition of hair growth
US6027882A (en) 1994-10-07 2000-02-22 The Regents Of The University Of California Patched genes and their use for diagnostics
US6946257B1 (en) * 1994-10-07 2005-09-20 Regents Of The University Of California Patched genes and uses related thereto
US6429354B1 (en) * 1994-10-07 2002-08-06 The Board Of Trustees Of The Leland Stanford Junior University Patched genes and uses related thereto
DK0804548T3 (da) 1994-10-07 2005-11-07 Univ Leland Stanford Junior Patched-gener og deres anvendelse
US6281332B1 (en) 1994-12-02 2001-08-28 The Johns Hopkins University School Of Medicine Hedgehog-derived polypeptides
US5643915A (en) 1995-06-06 1997-07-01 Andrulis Pharmaceuticals Corp. Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies
CA2232299A1 (en) 1995-09-21 1997-03-27 The Trustees Of Columbia University In The City Of New York Uses of bone morphogenetic proteins
DK0935656T3 (da) 1996-09-20 2006-12-11 Harvard College Hedgehog interagerende proteiner og anvendelser relateret dertil
US5990281A (en) 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
WO1998030576A1 (en) 1996-10-07 1998-07-16 The Johns Hopkins University School Of Medicine Novel hedgehog-derived polypeptides
US5759811A (en) 1996-11-13 1998-06-02 The Regents Of The University Of California Mutant human hedgehog gene
JPH10194987A (ja) 1997-01-14 1998-07-28 Youtai Iwamoto 骨・軟骨形成用組成物
DK1019490T3 (da) 1997-02-10 2010-03-15 Harvard College Fremgangsmåder til modulering af hæmatopoese og vaskulær vækst
JPH114695A (ja) 1997-04-25 1999-01-12 Hayashibara Biochem Lab Inc ヘッジホッグ蛋白質
US6051400A (en) 1997-05-23 2000-04-18 Smithkline Beecham Plc Patched-2 polypeptides and polynucleotides
AU8173098A (en) * 1997-06-27 1999-01-19 Ontogeny, Inc. Neuroprotective methods and reagents
US6218144B1 (en) 1997-06-30 2001-04-17 The Board Of Trustees Of The Leland Stanford Junior University Costal2 genes and their uses
AU8380898A (en) 1997-07-01 1999-01-25 Ingham, Philip W Vertebrate smoothened gene, gene products, and uses related thereto
US7144997B2 (en) 1997-07-24 2006-12-05 Curis, Inc. Vertebrate embryonic patterning-inducing proteins, compositions and uses related therto
EP1009424A2 (en) 1997-08-29 2000-06-21 Ontogeny, Inc. Regulation of muscle tissues by hedgehog-like polypeptides, and formulations and uses related thereto
WO1999039725A1 (en) 1998-02-06 1999-08-12 Eli Lilly And Company Desert hedgehog related nucleic acids and proteins

Also Published As

Publication number Publication date
WO1999004775A9 (en) 1999-04-29
EP1723950A2 (en) 2006-11-22
WO1999004775A2 (en) 1999-02-04
EP1067917A2 (en) 2001-01-17
US20030119729A1 (en) 2003-06-26
DE69832730D1 (de) 2006-01-12
US7144997B2 (en) 2006-12-05
DE69832730T2 (de) 2006-08-17
JP2001510796A (ja) 2001-08-07
US7138492B2 (en) 2006-11-21
EP1067917B1 (en) 2005-12-07
AU8589398A (en) 1999-02-16
WO1999004775A3 (en) 2000-11-23
ES2253822T3 (es) 2006-06-01
CA2297410A1 (en) 1999-02-04
US20070048286A1 (en) 2007-03-01
US20020045206A1 (en) 2002-04-18
ATE311863T1 (de) 2005-12-15

Similar Documents

Publication Publication Date Title
DK1067917T3 (da) Fremgangsmåde til behandling af dopaminerge og GABA-nerge lidelser
DE69829412D1 (de) Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
DE69736862D1 (de) System zur genetischen behandlung von stoerungen der herzleistung
NO970042L (no) 2-£(Dihydro)pyrazolyl-3'-oksymetylen|-anilider, fremgangsmåte til fremstilling og anvendelse derav
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
DE3789053D1 (de) Vorrichtung zur Behandlung von Hypertrophie der Vorsteherdrüse.
NO900704D0 (no) Fremgangsmaate og apparat til fremstilling av partikkelholdige plater.
DE69839014D1 (de) Apolipoprotein a-i agonisten und deren verwendung zur behandlung dyslipidämischer erkrankungen
IT8720689A0 (it) Procedimento e impianto per la separazione di sostanze leggere da miscele di substrati.
DK82093D0 (da) Fremgangsmaade til fremstilling af 6-chlor-7-iod-7-deazapuriner
ATE442156T1 (de) Verwendung von neuregulin zur beeinflussung der herzmuskelfunktion
DE3879928D1 (de) Prothetische vorrichtung zur erhoehung der nachgiebigkeit von arterien.
DK54090A (da) Fremgangsmaade og apparat til fremstilling af krumme formstofboejler, isaer busteholderboejler
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
NO882229L (no) Fremgangsmaate til hydrokrakking av hydrokarboner og apparat til utfoerelse av fremgangsmaaten.
IS4106A (is) Aðferð til framleiðslu á greinóttum 6-Azaandrostenones, milliefni og efni valin úr tilteknum amínum.
IT8523184A0 (it) Poliisocianati fluorurati ad elevata funzionalita' e vernici da essi ottenute.
DE69940980D1 (de) Rana pipiens proteine und deren verwendung in der behandlung von tumoren
DE69738985D1 (de) Raffinosesynthetase gen, verfahren zur herstellung von raffinose und transformierte pflanze
DK44688A (da) Beta-alkylmelatoniner, fremgangsmaade til fremstilling deraf og mellemprodukter til brug ved fremgangsmaaden
DK0935598T3 (da) 5-heteroatom-alkylsubstituerede 3-oxopyrido(1,2-a)benzimidazol-4-carboxamidderivater egnede til behandling af sygdomme i centralnervesystemet
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
IL143403A0 (en) Methods and compositions for treating disorders involving excitotoxicity
DE3575844D1 (de) Herbizide zusammensetzungen und verfahren zur bekaempfung von unkraut.
DK532087D0 (da) Farmaceutiske praeparater til behandling af hjernelidelser paa funktional og organisk basis